Janney Montgomery Scott LLC Increases Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Janney Montgomery Scott LLC lifted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 7.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,059,760 shares of the company’s stock after purchasing an additional 75,275 shares during the period. Janney Montgomery Scott LLC’s holdings in Aquestive Therapeutics were worth $3,073,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in AQST. Trust Point Inc. boosted its holdings in Aquestive Therapeutics by 69.9% in the 1st quarter. Trust Point Inc. now owns 23,396 shares of the company’s stock worth $68,000 after acquiring an additional 9,625 shares during the period. Sugar Maple Asset Management LLC purchased a new stake in Aquestive Therapeutics during the 1st quarter worth approximately $86,000. Penbrook Management LLC purchased a new position in shares of Aquestive Therapeutics during the 1st quarter valued at approximately $65,000. Two Sigma Advisers LP purchased a new position in shares of Aquestive Therapeutics during the 4th quarter valued at approximately $57,000. Finally, Two Sigma Investments LP grew its position in shares of Aquestive Therapeutics by 31.5% during the fourth quarter. Two Sigma Investments LP now owns 175,952 shares of the company’s stock worth $626,000 after buying an additional 42,160 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $3.21 on Wednesday. The stock’s 50 day moving average price is $2.88 and its 200 day moving average price is $3.02. The stock has a market cap of $318.85 million, a price-to-earnings ratio of -5.44 and a beta of 1.94. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $12.23 million. On average, sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Raymond James Financial set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an “outperform” rating and a $7.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $10.14.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.